Swiss-based biotechnology company OncoEthix has dosed the first patient in a Phase I study of its BET bromodomain inhibitor for treating patients with hematologic malignancies.

The BET inhibitor, OTX015, is a synthetic orally administered drug targeting BET bromodomain proteins 2/3/4 responsible for transcription of growth-promoting and cell cycle regulators.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Initially the trial will perform dose escalation studies in two parallel subsets of patients with acute leukemia and other hematologic malignancies to determine the optimum dosing regimen for OTX015.

The study will then evaluate safety, pharmacokinetics, pharmacodynamics and clinical activity in disease specific cohorts of at least 12 patients treated at the recommended dose.

OncoEthix CEO Bertrand Damour said, "We believe that OTX015 has the potential to be an important new drug in the continuing battle to improve and extend the lives of patients with cancer."

See Also:

During the company’s preclinical studies, the OTX015 induced potent anti-proliferative effects associated with cell cycle arrest, cellular senescence or apoptosis while treating acute leukemia (both cell lines and patients’ cells), various subtypes of lymphoma and multiple myeloma cell lines, according to the company.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Oncoethix said OTX015 was in-licensed from Mitsubishi Tanabe Pharma in March 2012, following completion of Phase I clinical studies in healthy volunteers.